© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Author | Peter Schmid, MD
Articles
Dr. Schmid Discusses the KEYNOTE-522 Trial
October 16, 2019
CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.
Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders
April 07, 2017
In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.